期刊文献+

辛伐他汀对心肌梗死大鼠心室重构与FoxO3a表达的影响 被引量:2

Effect of simvastatin on FoxO3a expression and ventricular remolding in rats with myocardial infarction
下载PDF
导出
摘要 目的探讨辛伐他汀对大鼠心肌梗死后心室重构和FoxO3a表达的影响。方法建立大鼠MI模型,24 h后存活大鼠随机分成心肌梗死组(MI组,n=8)、辛伐他汀20 mg组[20 mg/(kg.d),Sim组,n=8],并同时建立假手术组(Sham组,n=10)。4周后观察心室质量指数(LVWI)、天狼猩红染色分析左室非梗死区胶原容积分数(CVF)、HE染色观察心肌组织病理改变,RT-PCR和Western blot检测FoxO3a在非梗死区mRNA和蛋白表达水平。结果 MI组较Sham组LVWI[(2.62±0.16)vs(1.80±0.13),P<0.05]、非梗死区Ⅰ型胶原容积分数[(18.81±2.65)vs(5.01±0.84),P<0.05]、Ⅲ型胶原容积分数[(3.83±0.38)vs(1.52±0.23),P<0.05]及Ⅰ/Ⅲ比值[(4.96±0.90)vs(3.31±0.40),P<0.05]显著增加;左室心肌非梗死区FoxO3a mRNA[(0.29±0.05)vs(0.57±0.06),P<0.05]与蛋白[(0.28±0.04)vs(0.62±0.07),P<0.05]表达均降低。与MI组相比,Sim组LVWI[(2.27±0.08)vs(2.62±0.16),P<0.05]、非梗死区I型胶原容积分数[(9.26±1.13)vs(18.81±2.65),P<0.05]、Ⅲ型胶原容积分数[(2.37±0.23)vs(3.83±0.38),P<0.05]及Ⅰ/Ⅲ比值[(3.98±0.79)vs(4.96±0.90),P<0.05]均显著下降;但高于Sham组(P<0.05);左室心肌非梗死区FoxO3a mRNA[(0.49±0.06)vs(0.29±0.05),P<0.05]与蛋白[(0.38±0.08)vs(0.28±0.04),P<0.05]表达均显著增高;但低于Sham组(P<0.05),心肌组织病理结构得到改善。结论辛伐他汀能有效改善MI后心肌损伤和心室重构,其机制可能与其在基因转录和蛋白质翻译水平促进FoxO3a表达综合作用有关。 Objective To study the effect of simvastatin on ventricular remodeling and FoxO3a expression in rats with myocardial infarction(MI).Methods After a MI model of rats was established,24 survived rats were randomly divided into MI group(n=8),simvastatin treatment group(n=8) and sham-operation group(n=10).After 4 weeks,left ventricular weight index(LVWI) and collagen volume fraction(CVF) were detected in non-infarction zone(NIZ) with Picric-Sirius red staining.mRNA and protein expression of FoxO3a in NIZ was detected by reverse transcription polymerase chain reaction(RT-PCR) and Western blotting.Myocardial histopathology was examined with HE staining.Data were analyzed with the SAS 9.1 statistical software.Results The LVWI,types I and III CVF,and their ratio in NIZ were significantly higher in MI group than in sham operation(2.62±0.16 vs 1.80±0.13,18.81±2.65 vs 5.01±0.84,3.83±0.38 vs 1.52±0.23,and 4.96±0.90 vs 3.31±0.40,P0.05).The mRNA and protein expression level of FoxO3a in NIZ was significantly lower in MI group than in sham operation(0.29±0.05 vs 0.57±0.06,0.28±0.04 vs 0.62±0.07,P0.05).The LVWI,types Ⅰ and Ⅲ CVF,and their ratio in NIZ were significantly lower in simvastatin treatment group than in MI group(2.27±0.08 vs 2.62±0.16,9.26±1.13 vs 18.81±2.65,2.37±0.23 vs 3.83±0.38,and 3.98±0.79 vs 4.96±0.90,P0.05),which were higher than those in sham operation group(P0.05).The mRNA and protein expression level of FoxO3a in NIZ was significantly higher in simvastatin treatment group than in MI group(0.49±0.06 vs 0.29±0.05,0.38±0.08 vs 0.28±0.04,P0.05),which was lower than that in sham operation(P0.05).The improvement in lesions of myocardial tissue was better in simvastatin treatment group than in MI group(P0.05).Conclusion Simvastatin can effectively improve the ventricular remodeling in rats with MI.The mechanism of simvastatin may be related with its role in up-regulation of FoxO3a expression at gene transcription and protein translation level.
出处 《第三军医大学学报》 CAS CSCD 北大核心 2011年第3期266-269,共4页 Journal of Third Military Medical University
基金 重庆市卫生局医学科学技术项目(渝:2010-01-07)~~
关键词 心肌梗死 辛伐他汀 心室重构 FoxO3a(FKHRL1) myocardial infarction simvastatin ventricular remodeling foxo3a(FKHRL1)
  • 相关文献

参考文献16

  • 1Bujak M, Frangogiannis N G. The role of TGF-beta signaling in myocardial infarction and cardiac remodeling[ J]. Cardiovasc Res, 2007, 74(2) : 184- 195.
  • 2曹冬梅,卢建.叉头框(Fox)转录因子家族的结构与功能[J].生命科学,2006,18(5):491-496. 被引量:35
  • 3Evans-Anderson H J, Alfieri C M, Yutzey K E. Regulation of cardiomyocyte proliferation and myocardial growth during development by FOXO transcription factors[ J ]. Ciro Res, 2008, 102 (6) : 686 - 694.
  • 4Lee H Y, Chang J W, Youn S W, et al. Forkhead transcription factorFOXO3a is a negative regulator of angiogenic immediate early gene CYR61, leading to inhibition of vascular smooth muscle cell proliferation and neointimal hyperplasia[ J]. Circ Res, 2007, 100 (3) : 302 - 304.
  • 5Mogi M, Walsh K, Iwai M, et al. Akt-FOXO3a signaling affects human endothelial progenitor cell differentiation [ J ]. Hypertens Res, 2008, 31(1) : 153 -159.
  • 6Tan W Q, Wang K, Lv D Y, et aL Foxo3a inhibits cardiomyocyte hypertrophy through transactivating catalase[J]. J Biol Chem, 2005,283 (44) : 29730 -29739.
  • 7Skurk C, Izumiya Y, Maatz H, et al. The FOXO3a transcription factor regulates cardiac myocyte size downstream of AKT signaling [ J]. J Biol Chem, 2005, 280(21): 20814-20823.
  • 8Chiribau C B, Cheng L, Cucoranu I C, et al. FOXO3A regulates peroxiredoxin III expression in human cardiac fibroblasts [ J ]. J Biol Chem, 2008, 283(13): 8211 -8217.
  • 9Vahtola E, Louhelainen M, Forsten H, et al. Sirtuinl-p53, forkhead box 03a, p38 and post-infarct cardiac remodeling in the spontaneously diabetic Goto-Kakizaki rat[ J]. Cardiovas Diabetol, 2010, 9: 5.
  • 10肖祥彬,覃数,张冬颖,马康华.辛伐他汀改善心室重构与转化生长因子β1/Smad3信号途径的实验研究[J].中国药理学通报,2009,25(5):654-658. 被引量:5

二级参考文献95

  • 1张冬颖,覃数,唐显军,杨辉.辛伐他汀对大鼠心肌梗死后心室重塑影响的实验研究[J].中国药理学通报,2006,22(7):814-818. 被引量:15
  • 2张冬颖,覃数,唐显军,杨辉.辛伐他汀对心肌梗死后大鼠心肌间质重构的影响[J].中国药理学通报,2007,23(4):516-520. 被引量:9
  • 3Zhang J,Cheng X,Liao Y H,et al.Simvastatin regulates myocardial cytokine expression and improves ventricular remodeling in rats after acute myocardial infarction[J].Cardiovasc Drugs Ther,2005,19(1):13-21.
  • 4Bujak M,Frangogiannis N G.The role of TGF-β signaling in myocardial infarction and cardiac remodeling[J].Cardiovas Res,2007,74(2):184-95.
  • 5Jinnin M,Ihn H,Tamaki K.Characterization of SIS3,a novel specific inhibitoRof smad3,and its effect on transforming growth factor-1-induced extracellulaRmatrix expression[J].Mol Pharmacol,2006,69(2):597-607.
  • 6Bujak M,Ren G,Kweon H J,et al.Essential role of smad3 in infarct healing and in the pathogenesis of cardiac remodeling[J].Circulation,2007,116(19):2127-38.
  • 7Guo Y,Shi D Z,Yin H J,et al.Effects of tribuli saponins on ventricular remodeling after myocardial infarction in hyperlipidemic rats[J].Am J Chin Med,2007,35(2):309-16.
  • 8Li T S,Takahashi M,Suzuki R,et al.Pravastatin improves remodeling and cardiac function after myocardial infarction by an antiinflammatory mechanism rather than by the induction of angiogenesis[J].Ann Thorac Surg,2006,81(6):2217-25.
  • 9Martin J,Denver R,Bailey M,et al.In vitro inhibitory effects of atorvastatin on cardiac fibroblasts:implications foRventricular remodelling[J].Clin Exp Pharmacol Physiol,2005,32(9):697-701.
  • 10Hayashidani S,Tsmsui H,Shiomi T,et al.Fluvastatin,a 3-hydroxy-3-methylglutaryl coenzyme a reductase inhibitor,attenuates left ventricular remodeling and failure after experimental myocardial infarction[J].Circulation,2002,105(7):868-73.

共引文献69

同被引文献29

  • 1Oldberg A, Franzen A, Heingard D. Cloning and sequence analysis of rat bone sialoprotein (osteopontin) cDNA reveals an Arg-Gly-Asp cell- binding sequence[ J ]. Proe Natl Aead Sci U S A, 1986, 83 (23): 8819 - 8823.
  • 2Li C, Yang C W, Park J H, et al. Pravastatin treatment attenuates interstitial inflammation and fibrosis in a rat model of chronic cyclospo- rine-induced nephropathy[ J ]. Am J Physiol Renal Physiol, 2004, 286 (1): F46 - F57.
  • 3Rajamannan N M, Subramaniam M, Springett M, et al. Atorvastatin inhibits hypercholesterolemia-induced cellular proliferation and bone matrix production in the rabbit aortic valve [ J ]. Circulation, 2002, 105(22) : 2660 -2665.
  • 4Kusuyama T, Yoshiyama M, Omura T, et al. Angiotensin blockade inhibits osteopontin expression in non-infarcted myocardium after myocardial infarction [ J ]. J Pharmacol Sci, 2005, 98 (3) : 283 - 289.
  • 5Trueblood N A, Xie Z, Communal C, et al. Exaggerated left ventricular dilation and reduced collagen deposition after myocardial infarc- tion in mice lacking osteopontin[ J]. Circ Res, 2001,88(10) : 1080 - 1087.
  • 6张玉玲,周淑娴,雷娟,张静敏.血管紧张素Ⅱ-1型受体拮抗剂对心肌梗死大鼠骨桥蛋白表达及胶原沉积的影响[J].中国循环杂志,2007,22(4):307-310. 被引量:9
  • 7David A, Nichola F, Martin RB, et al. Akt regulates the survival of vascular smooth muscle cells via inhibition of FOXO3a and GSK3 [ J ]. J Biol Chem,2008,283 (28) : 19739 - 19747.
  • 8Lee HY, Chung JW, Youn SW, et al. Forkhead transcriptionfactor FOXO3a is a negative regulator of angiogenic immedi - ate early gene GYR61 ,leading to inhibition of vascular smooth muscle cell proliferation and neointimal hyperplasia[ J ]. Circ Res, 2007,1 00 (2) :302 - 304.
  • 9Tan WQ, Wang K, Lv DY, et al. Foxo3a inhibits cardiomyocyte hypertrophy through transactivating catalase [ J]. J BiolChem, 2008,283 (44) :29730 - 29739.
  • 10Chiribau CB, Cheng L, Cucoranu IC, et al. FOXO3A regulates peroxiredoxin m expression in human cardiac fibroblasts [ J ]. J Bio! Chem,2008,283(13) :8211 - 8217.

引证文献2

二级引证文献8

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部